Varenicline: An oral partial nicotine agonist for smoking cessation

Formulary

Volumn 41, Issue 6, 2006, Pages 265-272

  Feret, Brett ^a   Orr, Kelly ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; COMMIT; DIGOXIN; DOPAMINE; DRUGS USED IN THE TREATMENT OF ADDICTION; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE NASAL SPRAY; NICOTINE ORAL INHALER; NICOTINE PATCH; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTROL INHALER; PLACEBO; UNCLASSIFIED DRUG; VARENICLINE; WARFARIN;

ABNORMAL DREAMING; ADDICTION; ALLERGIC REACTION; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; DOPAMINE BLOOD LEVEL; DOPAMINE RELEASE; DOSE RESPONSE; DRUG APPROVAL; DRUG DEPENDENCE; DRUG HALF LIFE; DRUG SAFETY; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HICCUP; HUMAN; INSOMNIA; IRRITABILITY; MOUTH DISCOMFORT; NASAL PRURITUS; NAUSEA; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SUSTAINED DRUG RELEASE; TASTE DISORDER; THROAT IRRITATION; TOBACCO DEPENDENCE;

EID: 33745924968     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 1997-2001. MMWR. 2005;54:625-628.
2. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, Ga: US Department, of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. Available at: http://www.cdc.gov/tobacco/sgr/sgr_2004/index.htm. Accessed May 17, 2006.
3. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2004. MMWR. 2005;54:1121-1124.
4. The Health Consequences of Smoking: Nicotine Addiction: A Report from the Surgeon General. Atlanta GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1988. Available at: http://www.cdc.gov/tobacco/sgr/sgr_1988/index. htm. Accessed May 17, 2006.
5. US Public Health Service. Treating tobacco use and dependence-clinician's packet. A how-to guide for implementing the public health service clinical practice guideline, March 2003. Available at: http://www.surgeongeneral.gov/ tobacco/clinpack.html. Accessed May 17, 2006.
6. University of California, San Francisco. Rx for change website. Available at: http://rxforchange. ucsf.edu/. Accessed May 23, 2006.
7. Pfizer's varenicline receives U.S. FDA priority review [press release]. New York: Pfizer Inc; December 21, 2005. Available at: http://www.pfizer. com/pfizer/are/investors_releases/2005pr/mn_ 2005_1221.jsp. Accessed May 17, 2006.
8. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4 beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474-3477.
9. Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective alpha4 beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006;34:121-130.
10. Zyban [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005.
11. Oncken C,Watsky E, Reeves K, Anziano R, and the Varenicline Study Group. Smoking cessation with varenicline, a selective nicotinic receptor partial agonist: results from a Phase 2 study [abstract]. Presented at the Society for Research on Nicotine and Tobacco 2005 Annual Meeting; March 20-23, 2005; Prague, Czech Republic.
12. Oncken C, Watsky E, Reeves K, Anziano R, and the Varenicline Study Group. Varenicline is efficacious and well tolerated in promoting smoking cessation: results from a 7-week, randomized, placebo-and bupropion-controlled trial [abstract]. Presented at the Society for Research on Nicotine and Tobacco 2005 Annual Meeting; March 20-23, 2005; Prague, Czech Republic.
13. Tonstad S, Hays JT, Jorenby DE, et al. Smoking cessation efficacy and safety of an alpha4 beta2 nicotinic receptor partial agonist-results from varenicline in cessation therapy: optimizing results [abstract]. Presented at the 2005 Scientific Sessions of the American Heart Association (AHA); November 13-16, 2005; Dallas, Texas. Circulation. 2005;112:3363.
14. Data on file. New York: Pfizer, Inc; February 2006.
15. Faessel H, Burstein A, O'Gorman M, et al. Safety, tolerability, and pharmacokinetic evaluation of concomitant administration of varenicline and digoxin or warfarin [abstract]. Presented at the Society for Research on Nicotine and Tobacco 2005 Annual Meeting; March 20-23, 2005; Prague, Czech Republic.
16. Chantix [package insert]. New York, NY: Pfizer, Inc; 2006.